IS5101A - Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð - Google Patents

Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð

Info

Publication number
IS5101A
IS5101A IS5101A IS5101A IS5101A IS 5101 A IS5101 A IS 5101A IS 5101 A IS5101 A IS 5101A IS 5101 A IS5101 A IS 5101A IS 5101 A IS5101 A IS 5101A
Authority
IS
Iceland
Prior art keywords
cd40l
antibody
context
resistant
methods
Prior art date
Application number
IS5101A
Other languages
English (en)
Icelandic (is)
Inventor
L. Kalled Susan
W. Thomas David
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of IS5101A publication Critical patent/IS5101A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS5101A 1997-01-10 1999-06-30 Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð IS5101A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3467297P 1997-01-10 1997-01-10
US4015497P 1997-03-07 1997-03-07
PCT/US1998/000573 WO1998030241A1 (en) 1997-01-10 1998-01-09 Methods of therapeutic administration of anti-cd40l compounds

Publications (1)

Publication Number Publication Date
IS5101A true IS5101A (is) 1999-06-30

Family

ID=26711241

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5101A IS5101A (is) 1997-01-10 1999-06-30 Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð

Country Status (20)

Country Link
US (2) US20020071840A1 (https=)
EP (1) EP0966302B1 (https=)
JP (1) JP2001508450A (https=)
KR (2) KR20000070035A (https=)
CN (1) CN1248921A (https=)
AT (1) ATE356634T1 (https=)
AU (1) AU721697B2 (https=)
BR (1) BR9807471A (https=)
CA (1) CA2277223A1 (https=)
CZ (1) CZ244399A3 (https=)
DE (1) DE69837322T2 (https=)
EA (1) EA001426B1 (https=)
EE (1) EE9900275A (https=)
IL (1) IL130785A0 (https=)
IS (1) IS5101A (https=)
NO (1) NO993275L (https=)
NZ (1) NZ337073A (https=)
PL (1) PL193966B1 (https=)
TR (1) TR199902192T2 (https=)
WO (1) WO1998030241A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
BR9809641A (pt) * 1997-05-17 2000-07-11 Biogen Inc Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto
CN1261285A (zh) * 1997-06-20 2000-07-26 拜奥根有限公司 治疗性蛋白抑制剂综合症的cd154阻断治疗
NZ511034A (en) * 1998-09-21 2004-03-26 American Nat Red Cross Methods of downmodulating the immune response to therapeutic proteins
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
WO2001066141A1 (fr) * 2000-03-06 2001-09-13 Eisai Co., Ltd. Agents therapeutiques et prophylactiques diriges contre le syndrome des antiphospholipides
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
CA2781858C (en) 2000-05-12 2015-03-31 Genzyme Corporation Modulators of tnf-.alpha. signaling
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
ATE520400T1 (de) * 2002-11-21 2011-09-15 Genzyme Corp Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
EP2367849B1 (en) 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
WO2025117849A1 (en) 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235683A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
ES2143553T3 (es) * 1993-09-02 2000-05-16 Dartmouth College Anticuerpos anti-gp39 y sus utilizaciones.
NZ273208A (en) * 1993-09-02 2000-12-22 Dartmouth College Suppressing a humoral immune response against a thymus dependant (TD) antigen
ES2222463T3 (es) * 1993-12-23 2005-02-01 Immunex Corporation Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos.
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
US20050158314A1 (en) 2005-07-21
CA2277223A1 (en) 1998-07-16
KR20050088494A (ko) 2005-09-06
CZ244399A3 (cs) 1999-10-13
CN1248921A (zh) 2000-03-29
PL334500A1 (en) 2000-02-28
EE9900275A (et) 2000-02-15
KR100632846B1 (ko) 2006-10-16
WO1998030241A1 (en) 1998-07-16
AU721697B2 (en) 2000-07-13
DE69837322D1 (de) 2007-04-26
EA001426B1 (ru) 2001-02-26
BR9807471A (pt) 2000-03-21
DE69837322T2 (de) 2007-11-22
KR20000070035A (ko) 2000-11-25
JP2001508450A (ja) 2001-06-26
EP0966302B1 (en) 2007-03-14
AU5735398A (en) 1998-08-03
US20020071840A1 (en) 2002-06-13
HK1024424A1 (en) 2000-10-13
PL193966B1 (pl) 2007-04-30
TR199902192T2 (xx) 1999-12-21
EP0966302A1 (en) 1999-12-29
EA199900633A1 (ru) 2000-02-28
NZ337073A (en) 2001-01-26
IL130785A0 (en) 2001-01-28
NO993275D0 (no) 1999-07-01
ATE356634T1 (de) 2007-04-15
NO993275L (no) 1999-09-09

Similar Documents

Publication Publication Date Title
IS5101A (is) Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð
MY151032A (en) Treatment of tnf? related disorders
AU2003285874A8 (en) Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors
PL375041A1 (en) Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
NO20045056L (no) Fremgangsmater for behandling av hepatitt
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
IL192287A0 (en) Pharmaceutical compositions and methods for use
DE69739970D1 (de) Methode zur behandlung sexueller fehlfunktionen
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE302011T1 (de) PONAZURIL ZUR BEHANDLUNG VON DURCH COCCIDIA NEUROLOGISCHEN UND ßABORTIGENICß VERURSACHTEN ERKRANKUNGEN
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
ATE271384T1 (de) Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
DK1244442T3 (da) Fremgangsmåde til bestemmelse af nukleotidsynteseinhibitorer med færre bivirkninger